EUCTR2020-004721-23-ES进行中（未招募）1 期
A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation - Master Protocol of AMG 510 in Subjects with Advanced Solid Tumors With KRAS p.G12C
Amgen Inc.0 个研究点目标入组 1,000 人开始时间: 2021年11月10日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For the full list of inclusion criteria please refer to section 5.1 of the of the subprotocols.
- •All subprotocols
- •Pathologically documented, locally-advanced or metastatic NSCLC (subprotocol F)/ metastatic NSCLC with active brain metastases (subprotocol G) / metastatic colorectal cancer (suprotocol H, Part 1 and Part 2 cohort A, D, E+F)/ metastatic advanced solid tumor (subprotocol H Part 2 Cohort B)/ metastatic NCSLC (subprotocol H, Part 2 Cohort C) with KRAS p.G12C mutation identified through molecular testing. KRAS p.G12C mutation must be identified by an approved diagnostic device for detection of KRAS p.G12C in NSCLC or be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.
- •Measurable disease per RECIST 1.1 criteria (Section 11.8)
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2
- •Life expectancy of > 3 months, in the opinion of the investigator
- •Ability to take oral medications and willing to record daily adherence to investigational product
- •Corrected QT interval (QTc) = 470 msec for women and = 450 msec for men (based on average of screening triplicates
- •Adequate hematological laboratory assessments, as follows:
- •Absolute neutrophil count (ANC) = 1.5 x 109/L
- •Platelet count = 100 x 109/L
- •Hemoglobin = 9 g/dL
- •Adequate renal laboratory assessments, as follows:
- •Estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation = 60 ml/min/1.73 m2
- •Subprotocol F
- •Adequate hepatic laboratory assessments, as follows:
- •AST and ALT = 2.5 times the upper limit of normal (ULN), except if alkaline phosphatase > 2.5 times the ULN, then AST and/or ALT must be = 1.5 times the ULN
- •Total bilirubin = ULN
- •Adequate coagulation laboratory assessments, as follows:
- •Partial prothrombin time (PTT) or partial thromboplastin time (PTT) < 1.5 x ULN, OR international normalized ratio (INR) < 1.5 x ULN or within target range if on prophylactic anticoagulation therapy
- •Subprotocol H
- •Subjects must not have required dose reduction or been intolerant of a KRAS G12C inhibitor if they have received treatment with a KRAS G12C inhibitor in the past. A minimum of 2 subjects must be KRAS G12C inhibitor naïve per dose level. (Part 1)
- •Adequate hepatic laboratory assessments, as follows:
- •AST =2.5 x ULN (if liver metastases are present, =5 x ULN)
- •ALT = 2.5 x ULN (if liver metastases are present, = 5 x ULN)
- •Total bilirubin = 1.5 x ULN for Part 1 Cohort A, Part 2 Cohorts A to E
- •Total bilirubin =1 x ULN for Part 1 Cohort B and Part 2 Cohort F
- •Adequate coagulation laboratory assessments as follows:
- •PT or PTT or activated partial thromboplastin time = 1.5 x ULN, OR (INR) = 1.5 x ULN or within target range if on prophylactic anticoagulation therapy.
- •Subprotocol G:
- •Pathologically documented, metastatic NSCLC with KRAS p.G12C mutation
- •identified through molecular testing, and with active brain metastases. Subjects
- •must have received anti-PD-1 or anti-programmed death-ligand 1 (PD-L1)
- •immunotherapy (unless contraindicated) AND/OR platinum-based combination
- •chemotherapy AND targeted therapy (if actionable oncogenic driver mutations
- •were identified [eg; EGFR, ALK, and ROS1]), or if subject refused standard
- •therapy. KRAS p.G12C mutation must be identified by an approved diagnostic
- •device for detection of KRAS p.G12C in NSCLC or be performed in a Clinical
- •Laboratory Improvement Amendments (CLIA)-certified laboratory.
- •Metastatic brain disease meeting the following cri
排除标准
- •For the full list of exclusion criteria please refer to section 5.2 of the of the subprotocols.
- •All sub protocols
- •History or presence of hematological malignancies unless curatively treated with no evidence of disease = 2 years
- •History of other malignancy within the past 2 years, with the following exceptions:
- •Malignancy treated with curative intent and with no known active disease present for >2 years before enrollment and felt to be at low risk for recurrence by the treating physician.
- •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
- •Adequately treated cervical carcinoma in situ without evidence of disease.
- •Adequately treated breast ductal carcinoma in situ without evidence of disease.
- •Prostatic intraepithelial neoplasia without evidence of prostate cancer.
- •Adequately treated urothelial papillary non-invasive carcinoma or carcinoma in situ.
- •Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or cardiac arrythmia requiring medication
- •GI tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for IV alimentation, uncontrolled inflammatory GI disease (eg, Crohn’s disease, ulcerative colitis)
- •Exclusion of hepatitis infection based on the following results and/or criteria:
- •Positive Hepatitis B Surface Antigen (HepBsAg) (indicative of chronic Hepatitis B or recent acute hepatitis B)
- •Negative HepBsAg with a positive for hepatitis B core antibody (Hepatitis B core antibody testing is not required for screening, however if this is done and is positive, then hepatitis B surface antibody [anti-HBs] testing is necessary. Undetectable anti-HBs in this setting would suggest unclear and possible infection and needs exclusion).
- •Positive Hepatitis C virus antibody: Hepatitis C virus RNA by polymerase chain reaction (PCR) is necessary. Detectable Hepatitis C virus RNA suggests chronic hepatitis C
- •Known positive test for HIV
- •Has an active infection requiring systemic therapy
- •Received radiation therapy to the lung that is ? 30 Gy within 6 months of the first dose of trial treatment
- •Subprotocols F and H:
- •Active brain metastases and/or carcinomatous meningitis from non-brain tumors. Subjects who have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to study day 1 are eligible if they meet all of the following criteria: a) residual neurological symptoms grade = 2; b) on stable doses of dexamethasone, if applicable; and c) follow-up MRI performed within 30 days shows no new lesions appearing
- •Sub protocol H
- •Primary brain tumor
- •History of interstitial pneumonitis or pulmonary fibrosis, or evidence of interstitial pneumonitis or pulmonary fibrosis
- •Is unable to interrupt aspirin or other NSAIDs, other than an aspirin dose =1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).
- •Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy [except for subjects with history of breast cancer receiving adjuvant hormonal therapy], or investigational agent except for sotorasib) within 28 days of study day 1. Targeted small molecule inhibitors, within 14 days of study day 1, provided at least 5 half lives have passed.
- •Currently receiving treatment in another investigational device or drug study, or less than 28 days since last
研究者
相似试验
招募中
不适用
A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)colorectaal kanker / pancreas kankerDeadly tumors10017990cancerNL-OMON53961Amgen3
进行中（未招募）
1 期
Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)Advanced Solid Tumors with KRAS p.G12C MutationEUCTR2020-004721-23-ATAmgen Inc.1,200
招募中
1 期
Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)Advanced Solid Tumors with KRAS p.G12C MutationEUCTR2020-004721-23-BEAmgen Inc.1,200
招募中
1 期
Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)2023-506794-35-00Amgen Inc.136
招募中
1 期
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)JPRN-jRCT2031210121akatani iwami1,143